GSK withdraws Solzira NDA, will reformat data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline will reformat data from a trial of its gabapentin prodrug Solzira and resubmit the NDA as quickly as possible, the company says Nov. 10. GSK and partner XenoPort withdrew the NDA after FDA requested a reformatted presentation of data from the study for patients with restless legs syndrome. A 327-patient Phase III trial found a statistically significantly lower proportion of relapses in the treatment group (9 percent) versus the placebo group (23 percent) (1Pharmaceutical Approvals Monthly January 2008, p. 20). The drug would be the first non-dopaminergic agent for the treatment of RLS and would offer potential advantages over GSK's RLS drug Requip
You may also be interested in...
Restless Leg Syndrome Market Prepares To Move As GSK, UCB Advance Drugs
UCB could bring the first competitor to GlaxoSmithKline's Requip (ropinirole) for restless leg syndrome to market later this year after submitting an sNDA for Neupro (rotigotine) for RLS
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.